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Introduction
Diabetic macular edema (DME) is the leading cause for 
signi ficant loss of visual acuity in patients with diabetic retin-
opathy (DR).1 The treatment of DME remains problematic, 
with a high percentage of failures. In DR, the gold standard 
treatment of laser photocoagulation can indeed maintain and 
even improve the long-term condition of patients with base-
line visual acuity, but in others, it is ineffective and leads to 
 reduction of field of view, impaired color vision, and  sensitivity 
to contrast.2–4
The cause of DME is still under investigation, although 
it is believed that inflammation represents one of the  leading 
events in disease development. It has been observed that the 
increased permeability of macular capillaries in the course 
of hypoxia leads to increased levels of vascular endothelial 
growth factor (VEGF) and release of inflammatory factors, 
including chemokines, cytokines such as interleukin (IL)-6 
and IL-8, and prostaglandins.5,6 This, in turn, may cause the 
loss of endothelial cells and pericytes.7
According to this notion, intravitreal therapies with anti-
VEGF have been considered as an efficient treatment strategy 
for patients affected by DME.8,9 Nevertheless, not all patients 
respond to treatment, and the compliance to treatment is low 
because of the numerous injections required over time.10,11
It has been demonstrated that intravitreal administration 
of corticosteroids reduces capillary permeability and the for-
mation of secondary macular edema of various etiologies.12,13 
Corticosteroids also restrict the migration of leukocytes and 
inhibit the formation of VEGF factor, prostaglandins, and 
other proinflammatory cytokines.14,15 It seems that the route 
of administration of steroid drugs is crucial for the effective-
ness of their actions. The use of drugs administered directly 
into the vitreous body can achieve the appropriate concentra-
tion of the drug directly at the site of the disease, decreasing 
the systemic side effects.15
Dexamethasone is one of the most potent anti- inflammatory 
steroids. Its effect is six times stronger than intravitreal tri-
amcinolone acetonide, which is widely used in the treatment 
of  secondary macular edema, including DR,16 and 30 times 
more than cortisol.17 Triamcinolone acetonide is adminis-
tered as lipophilic crystals deposited in the vitreous for several 
months. However, this form of triamcinolone acetonide deposit, 
 administered at a dose of 1.2 and 4 mg in a single injection, does 
not provide a constant level of drug in the vitreous  chamber, 
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even during the initial period of observation, and is associated 
with side effects such as increased intraocular pressure and 
 steroid cataracts.18–20
In 2009, treatment with dexamethasone 0.7 mg, in an 
intravitreal implant of poly(lactic-co-glycolic acid) (PLGA), 
was introduced.21
The progressive biodegradation of PLGA makes  possible 
to obtain a constant daily release of dexamethasone in the 
 vitreous chamber for at least four months after a single  injection. 
With this method, the drug can produce enhanced thera peutic 
effects with reduced risk of adverse effects associated with 
 multiple injections or high drug concentration immediately 
after injection.22,23
In 2014, a sustained-release intravitreal 0.7 mg dexa-
methasone delivery system was approved by the Food and 
Drug Administration and Commission Européenne for the 
 treatment of DME, based on the MEAD study results.17 
However, data on its efficacy in the long term in patients 
affected by DME are still insufficient, and the results after 
six months are often contrasting, with studies showing either 
lasting or nonlasting therapeutic effects.
Thus, in this study, we evaluated the efficacy and safety of 
intravitreal injection of dexamethasone (Ozurdex® implant) 
in 17 patients affected by persistent DME resistant to anti-
VEGF therapy, within a follow-up of six months.
materials and methods
Patient selection. This was a retrospective study of 
consecutive patients affected by type 2 diabetes mellitus 
and DME.
The subjects were recruited at the Department of Sense 
Organs, Faculty of Medicine and Dentistry, Sapienza Univer-
sity of Rome, Italy. The study included 17 patients (19 eyes), 
14 males and 3 females. The mean age was 68 ± 9 years, and 
the mean duration of diabetes was 19.9 ± 5.29 years. The 
mean duration of DME was 45.4 ± 16.5 months (Table 1). 
In these patients, macular edema persisted for more than six 
months, despite treatments with grid macular photocoagula-
tion and anti-VEGF ranibizumab 0.5 mg intravitreal injec-
tions. The last injection of ranibizumab 0.5 mg was performed 
at least three months before starting the treatment with dex-
amethasone implant. After that, the anti-VEGF effect had 
completely worn off. Informed consent was obtained from 
all patients. The study was exempt from the requirement to 
obtain ethics committee approval, because it is a retrospective 
study of records.
The study adhered to the tenets of the Declaration of 
Helsinki for research involving human subjects.
Inclusion criteria. Criteria for inclusion were as follows: 
(1) age . 18 years old, (2) DME refractory to anti-VEGF 
therapy, (3) best-corrected visual acuity (BCVA) between 
table 1. demographic and clinical features of subjects with persistent dmE included in the study.
PatIEnt  
nO.
SEx agE
(YEaRS)
DURatIOn  
OF DME  
(MOnthS)
I.v. antI- 
vEgF
PREvIOUS  
PRP
SECOnD  
DExaMEthaSOnE  
InjECtIOn
CMt EtDRS
 1 m 79 28 yes yes no 736 4
 2 m 74 28 yes yes no 624 28
 3 F 74 28 yes no no 325 3
 4 F 88 30 yes yes yes 309 17
 5 m 56 26 (left eye) yes no no 720 28
27 (right eye) no no no 541 12
 6 m 61 40 yes yes no 487 18
 7 m 55 40 yes yes no 464 22
 8 m 70 38 yes yes no 357 12
 9 m 70 50 yes yes no 639 27
10 m 57 60 (left eye) yes no no 539 12
65 (right eye) no no no 326 11
11 m 68 75 (left eye) no no no 729 23
68 74 (right eye) yes no no 678 41
12 m 70 68 yes no no 654 24
13 m 69 52 yes yes no 366 34
14 m 72 85 yes yes yes 352 13
15 F 73 34 yes no no 688 16
16 m 64 38 yes yes no 520 4
17 m 59 40 yes no no 301 4
abbreviations: m, male; F, female; dmE, diabetic macular edema; iV, intravitreal; VEgF, vascular endothelial growth factor; pRp, panretinal photocoagulation.
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5 and 40 letters in the study eye at baseline examination 
(to ensure proper execution of functional examination), and 
(4) central macular thickness (CMT) .270 µm.
exclusion criteria. The exclusion criteria were as  follows: 
(1) structural damage (including atrophy of the retinal pig-
ment epithelium, subretinal fibrosis, laser scars,  epiretinal 
membrane involving fovea, or organized hard exudative 
plaques) within a 0.5 disc diameter of the center of the macula 
in the studied eye precluding improvement in visual acuity 
following the resolution of macular edema; (2) ocular surgery 
in the study eye in the last six months; (3) a history of ocular 
inflammation or (4) glaucoma; and (5) ocular hypertension in 
response to steroid treatment.
dme diagnostic criteria and evaluations. Baseline 
evaluation of vision was carried out before therapy (T0). 
 Fluorangiography (FAG) was performed to evaluate the pres-
ence of macular ischemia, while BCVA was assessed through 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
tables (62 × 64 cm) placed at a distance of 4 m following 
the protocol described in previous reports,8,9,23 by slit lamp 
biomicroscopy, ocular tonometry (using a Goldmann appla-
nation tonometer), fundus biomicroscopy, optical coherence 
tomography (OCT; for measurement of macular thickness 
and morphology using a Spectralis HRA-OCT produced by 
Heidelberg Engineering with a volumetric 512 × 49-scan) 
and color fundus photography. CMT was measured by 
 spectral-domain OCT.
BCVA and CMT examinations were carried out at 
 baseline (T0) and repeated after three days, one month (T1), 
three months (T3), four months (T4), and six months (T6) 
post injection.
All patients underwent a blood test for glycosylated 
hemoglobin (HbA1c).
efficacy criteria.
-	 Primary outcome measures included mean BCVA and 
CMT values at baseline and at all follow-up  visits. The 
implant was considered efficient when a mean improvement 
of BCVA $10 letters (two-line ETDRS) was observed.
-	 Secondary outcomes included the analysis of the retinal 
layer structure using OCT. The outcomes expected were a 
reduced mean CMT $250 µm. Evaluations of the integ-
rity of the external membrane and of the inner and outer 
segments of the photoreceptor interface were  carried out 
at baseline (T0) and repeated after three days (day 3), one 
month (T1), three months (T3), four months (T4), and 
six months (T6) post injection.
safety criteria. The appearance of undesired side effects 
correlated with the drug, such as inflammation of the anterior 
chamber, lens opacity, ocular pain, keratitis, or vitreous opac-
ity was monitored.
The side effects correlated with the surgical intervention, 
such as endophthalmitis, perforation of the eye, conjunctival 
hemorrhage, and systemic effects related to the drug, were 
also monitored.
Intraoperative procedure of intravitreal dexametha-
sone implant. All implants were performed under sterile 
conditions, after preparation of the conjunctiva using 5% 
povidone–iodine solution, topical anesthetic with ropivacaine, 
and positioning of the blepharostat. A 700 µg slow-release 
intravitreal dexamethasone implant (Ozurdex®) was placed in 
the vitreal cavity, behind the crystalline lens within 3 ± 2 days 
from baseline examination. All injections were performed in 
an operating room. The dexamethasone implant was inserted 
into the vitreous cavity through the pars plana using a cus-
tomized, single-use 22-gauge applicator. Patients were treated 
with a topical ophthalmic antibiotic (netilmicin sulphate) for 
seven days after treatment.
re-injection criteria. Starting from month 3, in patients 
with a loss of five letters in BCVA and recurrence/persistence 
of ME as documented by indirect fundus ophthalmoscopy 
and spectral-domain OCT, the treating physicians were free 
to decide whether to readminister an intravitreal dexametha-
sone implant.
statistical analysis. Data were analyzed by ANOVA 
with repeated measures followed by Fisher’s Protected Least 
Significant Difference (PLSD) post hoc test. A P-value 
,0.05 was considered statistically significant. Statistical 
analysis was performed using the Statview software from 
SAS Institute.
results
baseline values of clinical measurements. Before 
injection of the intravitreal dexamethasone implant, all the 
17 eyes included in the study had a significant edema of the 
retina. The average thickness of the retina at baseline was 
508.8 ± 164.05 µm, the medial BCVA was 19.16 ± 10.97, and 
average corrected intraocular pressure was 13.7 mmHg.
Visual acuity measured with early treatment dia-
betic retinopathy scale after intravitreal dexamethasone 
implant. The BVCA was measured using the Early Treatment 
Diabetic Retinopathy Scale (ETDRS). Repeated  measures 
ANOVA showed a significant effect of the treatment on 
ETDRS (P , 0.001; Fig. 1). Post hoc analyses showed that 
ETDRS values were significantly increased at T1, T3, and 
T4 (P , 0.001) as compared with baseline value (T0). At six 
months, we found that ETDRS values were still statistically 
higher as compared with baseline although to a lower signifi-
cance level (P , 0.001; Fig. 1).
cmt after intravitreal dexamethasone implant. As 
for ETDRS values, repeated measures ANOVA also showed 
a significant effect of intravitreal dexamethasone implant 
(P , 0.0001; Fig. 2). CMT significantly decreased at T1 and 
T3 (P , 0.001). At T4, CMT was still significantly lower 
than T0 (P , 0.05), while at T6, CMT values were not statis-
tically different from baseline (Figs. 2 and 3).
efficacy. The efficacy of the treatment, as demonstrated 
by CMT and ETDRS values reported in Table 2, had an 
effective rate of 100%.
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safety of intravitreal dexamethasone implant. The side 
effects correlated with intravitreal dexamethasone implant 
were monitored during the follow-up. No particular compli-
cations caused by either the implant or the drug itself were 
found. In addition, none of the eyes showed an increase in 
intraocular pressure requiring medical treatment.
retreatment. Two patients underwent a second injec-
tion at the end of the fourth month. In these patients, the 
HbA1c value was constantly over 8% as compared with 
the remaining patients where HbA1c value ranged from 
6.5% to 7%.
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Figure 1. Early treatment diabetic Retinopathy study (EtdRs) in 17 patients affected by persistent dmE and treated with intravitreal dexamethasone 
implant (Ozurdex®) over six months. 
notes: data are the mean ± sEm. Data are expressed in letters (ETDRS values). Asterisk (*) indicates significant difference versus baseline. **P , 0.01; 
***P , 0.001. 
abbreviations: t0, baseline; day 3, three days; t1, one month; t3, three months; t4, four months; t6, six months post injection.
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Figure 2. Cmt in 17 patients affected by persistent dmE and treated with intravitreal dexamethasone implant (Ozurdex®) over six months. 
notes: data are the mean ± sEm. Values are expressed in µm. Asterisk (*) indicates significant difference versus baseline. *P , 0.05; ***P , 0.001. 
abbreviations: t0, baseline; day 3, three days; t1, one month; t3, three months; t4, four months; t6, six months post injection. 
discussion
This study was performed to evaluate the efficacy of intravit-
real dexamethasone implant (Ozurdex), in patients affected by 
DME resistant to treatment with anti-VEGF. In particular, 
we evaluated the visual acuity and CMT during six months 
of follow-up. The results showed that dexamethasone implant 
induced an improvement of visual acuity, as measured by 
ETDRS, after one, three, four, and six months from implants. 
In addition, we observed a reduction of CMT after one, three, 
and four months from implants, while at T6, CMT values 
were not statistically different from baseline.
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These data demonstrate that the greatest eff icacy of 
dexa methasone is obtained within the first three months. 
After that, its therapeutic efficacy slowly decreases, although 
this effect is more pronounced in CMT than in BCVA mea-
surements. These findings are in line with other reports show-
ing that the anti-inflammatory action of dexamethasone is 
rapid and may produce beneficial effects within the first week 
of treatment.12,21,24–29 This effect might be attributable to the 
strong anti-inflammatory and antiedema properties of the 
dexamethasone. As stated in the introduction, it has been 
demonstrated that steroid administration may reduce VEGF 
expression, attenuate leukostasis, and vascular leakage and 
decrease the production of proinflammatory cytokines.14,15 
The fact that dexamethasone is able to improve DME symp-
toms in patients refractory to anti-VEGF suggests that in 
these cases inflammatory mediators may have a more impor-
tant role than VEGF in disease development. However, this 
hypothesis needs to be further investigated.
Our findings are in line with other reports where the effi-
cacy of dexamethasone lasted at least six months.12 Indeed, 
we found that only BCVA improvements were persistent at 
the end of the follow-up. The reason for these discrepancies 
among the effects of dexamethasone may be attributable to 
differences in individual response.
In our cohort, we found that only two patients neces-
sitated a second slow-release intravitreal dexamethasone 
implant after six months since ETDRS and CMT values were 
worse than those recorded at baseline. These patients were 
characterized by high HbA1c levels (above 7%) presumably 
caused by inadequate monitoring of glycemic levels. This find-
ing suggests that differences in other factors related to disease 
development, such as an inadequate therapeutic approach to 
diabetes, may cause a reduced response to dexamethasone in 
DME. Thus, the need for retreatment may not only be neces-
sarily due to a decrease in dexamethasone concentration in the 
vitreous but also due to a worsening of patient metabolic state 
caused by chronic diabetes.
Regarding dexamethasone safety profile, no  particular 
complications resulting from either the implant or the 
drug itself were found, a result in accordance with other 
reports.8,12,21 During the follow-up, none of the eyes showed 
increase in intraocular pressure requiring medical treatment. 
This finding has some relevance in clinical practice. In cases 
where prolonged duration of DME is associated with a 
reduced response to intravitreal anti-VEGF injection, the risk 
of complications due to repeated injection may significantly 
increase.9–11  Dexamethasone implants, having a duration of 
efficacy for at least three months, would extend the interval 
between injections and provide a better compliance for such 
patients. In addition, in the recent years, it has been proposed 
that the association of dexamethasone with other therapeutic 
strategies may produce significant structural retinal improve-
ments in these patients.30–32
Although our findings further provide evidence for the 
use of Ozurdex in DME, there are some limitations to our data 
interpretations. First, the number of eyes examined is  relatively 
low with a short follow-up period, and hence, it is difficult to 
table 2. EtdRs and Cmt values at baseline and in the successive 
follow-up points.
tIME POIntS vISUal aCUItY  
(nUMbER OF  
lEttERS EtDRS)
CMt (mM)
Baseline (T0) 19.16 ± 10.97 508.88 ± 164.05
3 days (Day 3) 21.23 ± 8.56 503.18 ± 124.06
1 month (T1) 26.56 ± 10.76 284.22 ± 113.13
3 months (T3) 28.16 ± 9.90 338.16 ± 109.78
4 months (T4) 26.38 ± 10.32 470.77 ± 154.28
6 months (T6) 21.66 ± 11.24 484.77 ± 167.43
note: data are the mean ± standard deviation.
Figure 3. OCt images of a patient with persistent diabetic macular edema. left eye, Cmt: (a) baseline; (b) three days; (C) one month; (D) three months; 
and (E) six months after treatment.
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reach definitive conclusions. Second, we  acknowledge that a 
control group is missing. Further studies with greater cohorts 
of subjects and longer follow-up are required to characterize 
the pharmacokinetics and therapeutic efficacy of dexametha-
sone implant in DME.
conclusion
In conclusion, our study demonstrates the efficacy and safety 
profile of the intravitreal dexamethasone implant within the 
six-month time frame. Our findings also suggest that chronic 
DME patients who do not respond to consecutive anti-VEGF 
treatment may benefit from switching the therapy to dexam-
ethasone implant, although individual response and metabolic 
state of the patient should be strictly monitored.
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